Skip to main content
. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646

Fig 7. Pharmacokinetic Profile of CCX168 in Healthy Human Volunteers.

Fig 7

Plasma concentration versus time profiles of CCX168 after (A) single oral doses of 1 mg (◊), 3 mg (∇), 10 mg (Δ), 30 mg (○), or 100 mg (□) CCX168 and (B) after receiving CCX168 once daily at 1 mg (◊), 3 mg (∇), or 10 mg (Δ), or twice daily at 30 mg (○) or 50 mg (□) for 7 days. The data points represent the mean ± standard error.